Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs AVXS 101 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors AveXis
- 03 Oct 2017 Top-line data as of August 7, 2017 will be presented at the 22nd International Annual Congress of the World Muscle Society (WMS), according to an AveXis media release. A manuscript regarding these data has been accepted for publication in a major medical journal.
- 03 Oct 2017 Top-line data as of August 7, 2017 presented in ann AveXis media release.
- 21 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History